Full-Time

Senior Clinical Research Associate

Clinical Monitoring

Posted on 8/15/2025

Altasciences

Altasciences

1,001-5,000 employees

Integrated CRO for early-phase drug development

No salary listed

Overland Park, KS, USA

Hybrid

Preferred candidate will reside near Dallas, TX or Atlanta, GA due to travel hub.

Category
Biology & Biotech (7)
, , , , , ,
Required Skills
Word/Pages/Docs
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • Bachelor's or equivalent health related (e.g., Medical, Scientific, Nursing) degree preferred.
  • Minimum of 5 years of clinically-related experience, of which a period of 2 years is preferable in clinical research monitoring or equivalent experience.
  • Knowledge of clinical research industry, terminology and practices.
  • Knowledge of regulations governing clinical research, ICH/GCP Guidelines and applicable regulations.
  • Strong verbal and written communication skills.
  • Familiarity with EDC systems; ability to learn required systems quickly and to train others, especially site staff.
  • Ability to meet deadlines, multitasks, and prioritize based on study needs.
  • Ability to make sound decisions based on available information.
  • Ability to establish and maintain a good working relationship with site personnel/ colleagues.
  • Ability to work both in a team and independently.
  • Ability to facilitate team meetings and teleconferences.
  • Ability to present at internal study team meeting(s).
  • Proficient with Microsoft Office Word, Excel and Power Point.
  • Strong planning and organizational skills and the ability to work effectively and efficiently in a dynamic environment with competing projects and deadlines.
  • Ability to travel.
Responsibilities
  • Create Clinical Monitoring Plans (CMPs) and prepare required Site Initiation Visits documents (e.g., Power Point presentations).
  • Perform site qualification, initiation, interim, and close-out visits (either on-site or remotely) accordingly to the CMPs.
  • Document activities via confirmation letters, visit reports, follow-up letters, and any other study-specific documents as per the CMP
  • Assess the sites processes.
  • Perform Source Documentation Verification (SDV) of source documents.
  • Perform dosing observations and/or assist to Investigational Products (IPs) dispensation.
  • Verify clinical data entered in the Case Report Forms (CRFs) and/or electronic CRFs (eCRFs).
  • Apply query resolution techniques and provide guidance to site staff as necessary, driving queries resolution within agreed timelines.
  • Review the Investigator Site Files (ISFs).
  • Review IPs inventory, reconciliation, and storage conditions.
  • Review and track Serious Adverse Events (SAEs).
  • Review study Protocols, Informed Consent Forms (ICFs) and any other study-specific documents.
  • Responsible for leading complex projects and involving multiple resources.
  • Interprets data to recommend plans and tactics.
  • Provides advice, guidance and answers to management on sensitive strategic matters pertaining to the entire organization.
  • Train study site personnel on the Protocol, study-specific documents, and applicable regulatory requirements in collaboration with assigned project team members.
  • Ensure monitoring SOPs and templates are up-to-date and update them as required.
  • At the site level: Assist with planning/scheduling, assigning, tracking, and overseeing the monitoring activities, including the internal reports revision.
  • Assists in managing and helping create clinical trial tracking metrics and reporting.
  • Mentoring, training for Clinical Research Associates.
  • Review and approve monitoring documents.
Desired Qualifications
  • Preferred candidate will reside in or near Dallas, TX or Atlanta, GA due to these locations being the travel hub for this role.

Altasciences provides an integrated CRO that handles the full early‑phase drug development path, from preclinical testing through clinical proof of concept and into manufacturing. Its approach combines discovery support, safety testing, clinical trial execution, and in‑house manufacturing to run programs under one roof. This contrasts with competitors that require pharma and biotech clients to source services from multiple vendors, adding complexity and risk; Altasciences streamlines the process by coordinating all steps. The company aims to help innovator drug programs move quickly and efficiently, delivering integrated data to de‑risk decisions and speed progression to later stages.

Company Size

1,001-5,000

Company Stage

Early VC

Total Funding

$6.7M

Headquarters

Laval, Canada

Founded

1976

Simplify Jobs

Simplify's Take

What believers are saying

  • Biotech/pharma consolidation demand for single-vendor early-phase development solutions increases.
  • 3D tissue technology adoption reduces animal testing costs and accelerates regulatory approval timelines.
  • Geographic footprint and participant database enable rapid enrollment for mid-size biopharma sponsors.

What critics are saying

  • Novo Holdings divesting Altasciences signals poor financial performance and operational cutbacks.
  • Charles River aggressive pricing on integrated packages captures 20% mid-size biopharma contracts.
  • AI-driven preclinical platforms from Insilico Medicine displace traditional animal safety pharmacology testing.

What makes Altasciences unique

  • Integrated CRO/CDMO spanning preclinical safety testing through Phase IV bioanalysis and manufacturing.
  • 9 North American facilities with 500,000+ participant database conducting 285+ trials annually.
  • VoxCell partnership integrates 3D tissue technology for human-relevant preclinical testing.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Employee Assistance & Telehealth Programs

Remote Work Options

Company News

GlobeNewswire
Mar 16th, 2026
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note

ISELIN, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard...

Business Wire
Aug 20th, 2025
Altasciences Receives EcoVadis Gold Medal for Environmental, Social, and Governance (ESG) Efforts

EcoVadis, the world's most trusted provider of business sustainability ratings, has collaborated closely with Altasciences to enhance its environmental, social, and governance (ESG) initiatives, underscoring the company's commitment to a sustainable future and a reduced environmental footprint.

Yahoo Finance
Jul 31st, 2025
Altasciences and VoxCell BioInnovation Announce Strategic Collaboration to Advance Preclinical Drug Development

This partnership combines Altasciences' comprehensive early-phase drug development capabilities with VoxCell's cutting-edge 3D tissue technology to offer a more predictive and human-relevant preclinical testing environment.

Postmedia Network
Mar 28th, 2025
Altasciences Receives 2025 CDMO Leadership Award in Small Molecule Dosage Form Category

For 14 years, Outsourced Pharma's CDMO Leadership Awards have recognized the top-performing contract development and manufacturing organizations based on comprehensive industry research, and feedback from sponsors.

BioSpace
May 29th, 2024
Altasciences Receives 2024 CRO Leadership Award for Capabilities

Altasciences receives 2024 CRO Leadership Award for Capabilities.

INACTIVE